Deng Junli, Wang Li, Chen Hongmin, Hao Jingli, Ni Jie, Chang Lei, Duan Wei, Graham Peter, Li Yong
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Oncotarget. 2016 Aug 23;7(34):55771-55788. doi: 10.18632/oncotarget.9908.
Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal transition and cancer stem cells play important roles in ovarian cancer chemoresistance and metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. In this review, we focus on the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer chemoresistance and explore the therapeutic implications for developing epithelial-mesenchymal transition and cancer stem cells associated therapies for future ovarian cancer treatment.
化疗耐药是复发性卵巢癌治疗的主要挑战,也是治疗失败和临床预后不佳的原因。了解卵巢癌化疗耐药的机制将有助于预测疾病进展、开发新疗法并实现全身治疗的个性化。在过去十年中,越来越多的证据表明上皮-间质转化和癌症干细胞在卵巢癌化疗耐药和转移中发挥重要作用。针对上皮-间质转化和癌症干细胞的治疗有望改善当前的卵巢癌治疗方法,并在未来延长复发性卵巢癌患者的生存期。在本综述中,我们重点关注上皮-间质转化和癌症干细胞在卵巢癌化疗耐药中的作用,并探讨开发与上皮-间质转化和癌症干细胞相关疗法对未来卵巢癌治疗的意义。